Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amylx Pharmaceuticals Inc (AMLX) vs Burlington Stores Inc (BURL) Price & Performance

Amylx Pharmaceuticals IncTrade
Burlington Stores IncTrade

Price performance (Past 24H)

Key statistics

Amylx Pharmaceuticals Inc vs Burlington Stores Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Burlington Stores Inc trades at $354.86 (market cap $22.59B). The key difference: Burlington Stores Inc is far larger — about 8.6× Amylx Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

AMLXBURL
Market Cap
$2.64B$22.59B
Sector
HealthConsumer Cyclical
52-Week High
$24.19$372.19
52-Week Low
$7.82$242.43
Enterprise Value
$2.39B$27.71B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amylx Pharmaceuticals Inc

AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.

The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.

Burlington Stores Inc

Burlington Stores (BURL) trades at $351.88, down 5.28% today but maintains strong technical support near $352. The company demonstrates robust fundamentals with revenue growth from $10.63B to $11.9B projected for 2026, net income margin expansion to 5.23%, and consistent earnings beats. Recent news highlights successful smaller-store strategy execution and multiple analyst upgrades. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $352 and resistance at $365.

BURL presents a compelling growth story with 94% analyst buy ratings and a $367 consensus target offering 4.3% upside. The retailer's margin expansion and store productivity improvements drive optimism, though competitive pressures and consumer spending sensitivity pose risks. Institutional ownership trends show mixed activity with recent insider selling offset by fund position increases.

Returns comparison

Trailing returns across standard periods

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX

About Burlington Stores Inc

Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.

Read more on BURL